Phase 2 Study of Ceritinib in Patients With Unresectable Melanoma
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Ceritinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 08 Nov 2019 Status changed from recruiting to suspended.
- 19 Jun 2018 Status changed from not yet recruiting to recruiting.
- 20 Apr 2018 New trial record